17395-31-2

Basic information

• Product Name: 7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidyl)-2-oxopropyl]quinazolin-4(3H)-one monohydrobromide
• Synonyms: 7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidyl)-2-oxopropyl]quinazolin-4(3H)-one monohydrobromide
• CAS NO: 17395-31-2
• Molecular Formula: C16H18Br2ClN3O3
• Molecular Weight: 495.59342
• EINECS: 241-422-7
• Mol File: 17395-31-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 595.8°Cat760mmHg
• Flash Point: 314.1°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 4.84E-15mmHg at 25°C
• CAS DataBase Reference: 7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidyl)-2-oxopropyl]quinazolin-4(3H)-one monohydrobromide(CAS DataBase Reference)
• NIST Chemistry Reference: 7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidyl)-2-oxopropyl]quinazolin-4(3H)-one monohydrobromide(17395-31-2)
• EPA Substance Registry System: 7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidyl)-2-oxopropyl]quinazolin-4(3H)-one monohydrobromide(17395-31-2)

Safety Data

• Hazardous Substances Data: 17395-31-2(Hazardous Substances Data)

Usage

General Description

7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidyl)-2-oxopropyl]quinazolin-4(3H)-one monohydrobromide is a chemical compound with a complex structure. It contains a quinazolinone core with a bromo and a chloro substituent on the 7th and 6th positions, and a piperidyl group attached to the 3rd position through a 2-oxopropyl chain. The presence of a monohydrobromide salt suggests that it can form hydrogen bonds and interact with other charged molecules. 7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidyl)-2-oxopropyl]quinazolin-4(3H)-one monohydrobromide may have potential pharmaceutical applications due to its diverse structural features, which could influence its interactions with biological targets such as enzymes or receptors. However, further research is needed to fully understand its properties and potential uses.

InChI:InChI=1/C16H17BrClN3O3.BrH/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14;/h5-6,8,14-15,19,23H,1-4,7H2;1H

Upstream product

• 64544-00-9 2,3-cis-2-bromoacetonyl-3-methoxy-1-piperidinecarboxylic acid allyl ester 
• 64544-01-0 7-bromo-6-chloro-3-[3-(3-hydroxyl-2-piperidyl)-2-oxopropyl]quinazolin-4(3H)-one 
• 1203455-28-0 (2R,3S)-3-benzyloxy-2-[2-oxo-3-(7-bromo-6-chloro-4-oxoquinazolin-3(4H)-yl)propyl]piperidine-1-carboxylic acid benzyl ester 
• 879899-01-1 (2R,3S)-3-benzyloxy-2-(2-oxopropyl)piperidine-1-carboxylic acid benzyl ester 
• 304665-09-6 (2R,3S)-benzyl 2-allyl-3-(benzyloxy) piperidine-1-carboxylate 
• 866488-35-9 (E)-benzyl (4-hydroxy-7-oxooct-5-en-1-yl)carbamate 
• 1091605-50-3 (2R,3S)-3-hydroxy-2-(2-oxopropyl)piperidine-1-carboxylic acid benzyl ester 
• 1091605-49-0 (+)-(S,E)-benzyl (4-hydroxy-7-oxooct-5-en-1-yl)carbamate 

Downstream Products

• 55837-20-2 halofuginone 
• 55837-20-2 (+)-halofuginone 

Relevant articles and documents

New synthesis process for preparing veterinary bulk drug halofuginone hydrobromide

The invention discloses a process method for preparing veterinary raw material drug halofuginone hydrobromide, and relates to the field of veterinary drugs and the technical field of drug synthesis. According to the invention, a novel process route is adopted, 7-bromo-3-(8-bromo-5-hydroxy-2-oxo-3-octenyl)-6-chloro-4 (3H)-quinazolinone is taken as a starting raw material, and the halofuginone hydrobromide is prepared through three-step reaction of ammonolysis, purification and salification, so that the problems of difficulty in obtaining raw materials, harsh reaction conditions, high cost and the like in the existing synthesis method are solved. The novel synthesis process for preparing the veterinary drug halofuginone hydrobromide is simple in process operation, low in production cost, few in steps, high in total yield, small in pollution and suitable for industrial mass production.

Synthetic method for halofuginone and intermediate of halofuginone

The invention relates to a synthetic method for halofuginone and an intermediate of the halofuginone. The reaction formula is shown in the description, wherein R1 is one selected from the group consisting of methyl, ethyl, n-propyl, isopropyl and t-butyl; R2 is one selected from the group consisting of methyl and ethyl; and R3 is one selected from the group consisting of methoxyformyl, ethoxyformyl, tert-butoxyformyl, benzyloxyformyl, trichloroethoxyformyl and benzyl. The synthetic method provided by the invention has the advantages of a simple process, low costs, few by-products in the synthetic process, a simple purification process, no need of column chromatography purification, a high product yield, less impurities, high purity, and controllable product quality, easily meets ICH declaration requirements and can be used for industrial production of the halofuginone.

A convergent strategy towards febrifugine and related compounds

We report a modular five step synthetic route to the febrifugines that employs 2-(chloromethyl)allyl-trimethylsilane as a conjunctive reagent for the coupling of the piperidine and quinazolinone groups. We also demonstrate the application of a recent Rh-catalyzed quinazolinone synthesis for the facile generation of febrifugine analogs.